Call it a major milestone in bladder cancer therapy that aims to provide a lifeline for patients who previously had limited options
Elevidys came under scrutiny in June when the FDA disclosed two fatal cases in non-ambulatory boys who developed dangerously high liver enzyme levels
Adzynma, approved for both adults and children with cTTP, is a recombinant enzyme therapy designed to replace the deficient ADAMTS13 enzyme
Tofacitinib extended-release tablets are a Janus kinase inhibitor indicated for Rheumatoid Arthritis
The full approval is based on the results from the pivotal Phase 3 EPCORE FL-1 study
The study successfully met its primary endpoint, demonstrating similar rates of viral suppression for DOR/ISL compared to Biktarvy at 48 weeks
Subscribe To Our Newsletter & Stay Updated